Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Combating Eye Injuries With a Reversible Superglue Seal

By USC Health Sciences | December 8, 2017

Scientists and engineers at USC have developed an on-the-spot, temperature-sensitive gel that could seal eye injuries on the battlefield. Source: N. Bayat et al., Science Translational Medicine (2017)

When a soldier sustains a traumatic eye injury on the battlefield, any delay in treatment may lead to permanent vision loss. With medical facilities potentially far away and no existing tools to prevent deterioration, medics are in a high-stakes race against the clock.

A multidisciplinary team of scientists and engineers at USC are close to solving the problem. They have developed a reversible, temperature-sensitive temporary seal that changes from a fluid to a super-strong semi-solid when applied to the eye. When the patient is ready for surgery to permanently close the injury, doctors can remove the seal by adding cool water.

Results of the study were published on Dec. 6 in Science Translational Medicine.

“If you look at historical data over the last several decades, the rate of war-related ocular injuries has steadily increased from a fraction of a percent to as high as 10 to 15 percent. Some of that can be attributed to changes in warfare, especially with the use of improvised explosive devices,” says corresponding author John Whalen, assistant professor of research ophthalmology at the USC Roski Eye Institute and member of the USC Institute for Biomedical Therapeutics. “When the Department of Defense asked the scientific community to develop novel approaches to treating ocular injuries, we immediately thought of an advanced material we had previously worked with as a possible adhesive for a retinal implant.”

The study represents the latest development from the USC Institute for Biomedical Therapeutics, which fosters collaborations between scientists at the Keck School of Medicine of USC, chemists at the USC Dornsife College of Letters, Arts and Sciences and engineers at the USC Viterbi School of Engineering. USC has made research in convergent bioscience and biotechnology a priority to address health issues across the lifespan through the development of new diagnostic tools, treatments and biomedical devices.

A custom fit

The material the group was working with for retinal implants was a hydrogel called PNIPAM, poly(N-isopropylacrylamide), which had a unique attribute that made it a natural fit for this application: When cooled, the hydrogel became a liquid for easy application, and when heated, it became a viscous semi-solid with strong adhesion. All that was needed was some tailoring.

“Since the initial hydrogel’s transition temperature was very close to the temperature of the human eye, we had to modify its properties to ensure that it would form a solid seal as soon as the gel was applied to the eye by a soldier or medic,” says lead author Niki Bayat, a doctoral candidate in the Mork Family Department of Chemical Engineering and Materials Science at the USC Viterbi School. “Providing a perfect, yet reversible seal, the smart hydrogel shows promise for the next generation of tissue adhesives.”

When an ophthalmologist is ready to repair the eye, the hydrogel can be extracted by applying cool water and converting it back to a less adhesive state.

Special delivery

The research team also developed a special syringe for the hydrogel that would be easy to use on the front lines and capable of quickly cooling the hydrogel before application. The syringe has a cooling chamber filled with calcium ammonium nitrate crystals — the type that are used in instant ice cold packs. By adding water to the chamber, the crystals activate and cool the hydrogel to operating temperatures within 30 seconds.

“We were able to optimize the delivery device so that it not only rapidly cools the hydrogel but also holds it at that temperature, giving users a 10-minute window to fill penetrations in the eye,” Whalen says. “It’s very simple to use — almost like caulking a bathroom seal.”

The customized seal and delivery device will also reduce the amount of time it takes to close penetrating eye injuries overall.

“This temporary intervention could decrease repair time from 30 minutes or longer to less than five minutes, freeing up valuable time for first responders and trauma units,” says principal investigator Mark Humayun, university professor of ophthalmology and co-director of the USC Roski Eye Institute and director of the USC Institute for Biomedical Therapeutics.

To establish the material’s efficacy, a rabbit model was used. Results showed that when applied to eyes with penetrating injuries, the hydrogel improved pressure within the eye, which may be critical for preventing retinal detachment that can ultimately lead to vision loss. There also was no evidence of inflammation or infection for up to four weeks of use. The researchers hope to initiate clinical safety testing in humans in 2019.

Whalen envisions applications for the hydrogel that go beyond the battlefield.

“First responders at a mass casualty incident could deploy the hydrogel while patients wait for their injuries to be completely repaired by an ocular surgeon in appropriate microsurgical facilities,” he says. “It could also be useful in ERs in rural areas where there isn’t an eye center with such capabilities nearby. It may even have potential for temporarily treating gunshot wounds.”


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE